Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice

Blog Article

The recent arrival of CDK4/6 inhibitor agents, with an approximate doubling of progression-free survival (PFS) associated Darkroom Equipment with their use in hormone receptor-positive, HER2-negative advanced breast cancer (BC), has radically changed the approach to managing this disease.However, resistance to CDK4/6 inhibitors is considered a near-inevitability in most patients.Mechanisms of resistance to these agents are multifactorial, and research in this field is still evolving.

Biomarkers with the ability to identify early resistance, or Anti-Fatigue Mats to predict the likelihood of successful treatment using CDK4/6 inhibitors are yet to be identified, and represent an area of unmet clinical need.Here we present selected mechanisms of resistance to CDK4/6 inhibitors, largely focussing on roles of Rb, cyclin E1, and the PIK3CA pathway, with discussion of associated biomarkers which have been investigated and applied in recent pre-clinical and clinical studies.These biological drivers may furthermore influence clinical treatment strategies adopted beyond CDK4/6 resistance.